Top Page
MediPharm Labs
(TSX:LABS)
MediPharm Labs (LABS) vs. iShares MSCI Canada ETF (EWC)
MediPharm Labs Business Overview & Revenue Model
MediPharm Labs Earnings Call Summary
MediPharm Labs Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 41.96M | 33.06M | 22.12M | 21.71M | 36.01M |
| Gross Profit | 12.80M | 5.85M | -1.91M | -15.25M | -43.98M |
| EBITDA | -7.52M | -10.48M | -27.09M | -38.55M | -53.40M |
| Net Income | -10.69M | -13.08M | -29.98M | -54.80M | -67.11M |
Balance Sheet | |||||
| Total Assets | 53.73M | 63.94M | 65.50M | 92.36M | 118.23M |
| Cash, Cash Equivalents and Short-Term Investments | 11.69M | 17.98M | 24.14M | 34.11M | 19.91M |
| Total Debt | 388.00K | 2.29M | 632.00K | 216.00K | 18.46M |
| Total Liabilities | 10.55M | 10.93M | 9.49M | 9.21M | 39.82M |
| Stockholders Equity | 43.18M | 53.01M | 56.01M | 83.15M | 78.41M |
Cash Flow | |||||
| Free Cash Flow | -5.01M | -12.81M | -16.93M | -14.00M | -45.28M |
| Operating Cash Flow | -4.86M | -12.34M | -16.07M | -13.21M | -37.77M |
| Investing Cash Flow | 413.00K | 6.87M | 5.16M | 35.00K | -7.45M |
| Financing Cash Flow | -1.85M | -368.00K | 796.00K | 27.80M | 26.42M |
MediPharm Labs Technical Analysis
MediPharm Labs Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | €4.82B | 18.16 | -49.50% | 1.91% | 13.92% | -2.48% | |
48 Neutral | $29.06M | ― | -16.22% | ― | 16.24% | 46.47% | |
| $24.56M | 6.25 | ― | ― | ― | |||
| $13.20M | ― | -74.75% | ― | ― | ― | ||
| $29.45M | 3.04 | 20.78% | ― | ― | ― | ||
| $28.89M | ― | -24.12% | ― | ― | ― | ||
| $22.03M | ― | -203.40% | ― | ― | ― |
MediPharm Labs Corporate Events
MediPharm Labs announced the results of its 2025 Annual and Special Meeting of Shareholders, where key resolutions were approved, including setting the number of directors at seven and appointing MNP LLP as auditors. The company welcomed new directors Emily Jameson and John Medland, while acknowledging the contributions of outgoing director Michael Bumby. These changes, along with the approval of unallocated awards under the equity incentive plan, position MediPharm for future growth and stability, reinforcing its strategic direction and commitment to stakeholders.
MediPharm Labs has cautioned its shareholders to await the final results of its annual and special meeting, countering a premature claim by Apollo Technology Capital Corporation regarding the meeting’s outcome. The company emphasizes that the meeting has yet to occur and assures stakeholders that results will be announced in compliance with legal and stock exchange requirements, highlighting the importance of accurate information dissemination.
MediPharm Labs urges shareholders to vote in favor of its current strategy and board nominees ahead of the June 13 deadline, emphasizing its successful transformation and financial improvements. The company criticizes Apollo Technology Capital Corp.’s alternative plan as inadequate and misleading, highlighting MediPharm’s strong financial position and growth prospects.
MediPharm Labs announced that the Superior Court of Justice in Ontario has dismissed an application by Apollo Technology Capital Corporation and Nobul Technologies Inc., which sought to appoint a third-party independent chair for MediPharm’s upcoming Annual and Special Meeting of Shareholders. The court found no evidence of unfair conduct by MediPharm’s proposed meeting chair. The decision supports MediPharm’s commitment to a fair shareholder meeting process, reinforcing its industry positioning and signaling stability to its stakeholders.
MediPharm Labs has completed the sale of its Hope, British Columbia facility for $4.5 million and plans to expand its EU GMP-certified cultivation capacity in Napanee, Ontario by 30% in 2025. This strategic move aims to optimize operational efficiency and financial strength by divesting non-core assets and enhancing international growth potential. The expansion will help meet the growing demand for pharmaceutical cannabinoid products, particularly in Europe and Australia, while improving the company’s cash position and financial flexibility.
MediPharm Labs announced that Institutional Shareholder Services (ISS) has recommended shareholders vote in favor of the company’s nominees for the Board of Directors, rejecting Apollo’s arguments for change. The ISS report highlighted MediPharm’s significant financial improvements, including increased revenues and gross margins, under CEO David Pidduck’s leadership. This endorsement supports MediPharm’s strategic growth focus and suggests that Apollo’s claims of mismanagement are unfounded.
MediPharm Labs has responded to fabricated allegations from Apollo Technology Capital Corporation, which the company claims are part of a misinformation campaign to gain control of its board. MediPharm has recently completed a clean year-end audit and is taking legal action against Apollo for material misstatements. The company’s operations remain compliant with international standards, and it continues to focus on its strategic growth and market positioning.
MediPharm Labs’ Board of Directors has issued a letter to shareholders in response to a dissident plan proposed by Apollo Technology Capital Corp., which seeks control of the company. The Board argues that Apollo’s plan lacks specifics and could jeopardize the company’s recent progress and relationships with stakeholders, urging shareholders to support the current Board’s nominees in the upcoming vote.
MediPharm Labs has commenced production of its novel cannabis metered dose inhalers for the EU and UK markets under a distribution agreement with Blackpoint Limited. This product provides a smoke-free, precise dosing option for patients, aligning with MediPharm’s mission to advance global access to pharma-grade cannabinoid wellness products. The launch is part of MediPharm’s strategy to expand internationally, leveraging its GMP certifications and distribution partnerships. The inhaler is designed for medical applications, offering a discreet and effective delivery method similar to asthma inhalers, and is expected to impact the European medicinal cannabis market significantly.
MediPharm Labs has issued a cautionary statement to its shareholders regarding the governance failures of three dissident nominees, who are associated with Apollo Technology Capital Corporation, seeking election to its board. These nominees have been linked to questionable governance practices at Check-Cap Ltd., including poor transparency, questionable financial transactions, and failure to execute business promises, raising concerns about their potential impact on MediPharm’s board and shareholder value.
MediPharm Labs has announced the removal of all conditions for the sale of its Hope Facility to Rubicon Organics for $4.5 million in cash, with the transaction set to close in June 2025. This sale is part of MediPharm’s strategy to streamline operations and reduce costs, having already saved approximately $42 million annually since 2022. The proceeds will enhance the company’s cash position and support its focus on international growth and acquisition opportunities.
MediPharm Labs has raised concerns about the qualifications of six dissident nominees proposed by Apollo Technology Capital Corporation for its board of directors. The company highlights the nominees’ insufficient experience in the cannabis and pharmaceutical sectors, limited public company board experience, and potential conflicts of interest, which could impact the company’s operations and shareholder value.
MediPharm Labs reported strong financial results for Q1 2025, achieving positive adjusted EBITDA and an 11% increase in revenue compared to Q1 2024. The company’s international medical cannabis revenue grew by 87%, forming 55% of total revenue, and gross profit improved significantly. MediPharm’s strategic cost reductions and revenue growth have strengthened its financial position, making it virtually debt-free with a strong cash balance, positioning it favorably against peers burdened with debt.
MediPharm Labs has filed its proxy materials for the upcoming Annual and Special Meeting of Shareholders, emphasizing the importance of shareholder support for the current Board nominees. The company reported a 27% increase in net revenue and improved gross profit margins in 2024, alongside a narrowed Adjusted EBITDA loss, showcasing the effectiveness of its strategic revitalization. Despite these achievements, a dissident shareholder, Apollo Technology Capital Corp., is challenging the current Board with alternative nominees, raising concerns about potential disruptions to MediPharm’s positive momentum.
MediPharm Labs announced it will release its first quarter financial results for 2025 on May 14, along with a conference call and webcast to discuss the results. This announcement underscores the company’s ongoing commitment to transparency and its strategic positioning in the pharmaceutical cannabis industry. The release of financial results and the subsequent discussion could provide stakeholders with insights into the company’s operational performance and future prospects.
MediPharm Labs is responding to a dissident proxy circular filed by Apollo Technology Capital Corporation, which proposes new board nominees. MediPharm criticizes Apollo’s lack of a viable plan and questions the leadership of its nominees. The company highlights procedural non-compliance in Apollo’s filing and urges shareholders to await further details in its upcoming Management Information Circular. MediPharm remains confident in its current board and strategy to drive growth and value.
MediPharm Labs reported a 27% increase in annual net revenue to $42 million for 2024, driven by significant growth in international medical cannabis revenue. The company improved its profitability, reduced operating expenses, and enhanced its gross profit margin. Key operational changes included transitioning operations to the Barrie facility, resulting in cost savings, and the sale of the Hope facility. MediPharm’s strong cash position and debt-free status, along with its focus on international markets and clinical research, position it well for future growth.